Deutsch English Français

Contact

EP1599504

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP1599504

EP1599504 - MODIFIED ANTIBODY [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 09.10.2015 Database last updated on 03.06.2024
Most recent event Tooltip	25.08.2017	Lapse of the patent in a contracting state New state(s): BG	published on 27.09.2017 [2017/39]
Applicant(s)	For all designated states Vaccibody AS Gaustadalleen 21 N-0349 Oslo / NO
	[2009/09]
Former [2005/48]	For all designated states MEDINNOVA AS Rikshospitalet, Sognsvannsveien 20 0027 Oslo / NO
Inventor(s)	01 / BOGEN, Bjarne Pelvikveien 28 1367 Snaroya / NO
	02 / FREDRIKSEN, Agnete, Brunsvik Strandveien 5 2005 Raelingen / NO
	03 / SANDLIE, Inger Roaveien 16A 0752 Oslo / NO
	[2014/28]
Former [2005/48]	01 / BOGEN, Bjarne Pelvikveien 28 N-1367 Snaroya / NO
	02 / FREDRIKSEN, Agnete, Brunsvik Strandveien 5 N-2005 Raelingen / NO
	03 / SANDLIE, Inger Roaveien 16A N-0752 Oslo / NO
Representative(s)	Inspicos P/S Agern Allé 24 2970 Hørsholm / DK
	[N/P]
Former [2014/49]	Inspicos A/S Kogle Allé 2 P.O. Box 45 2970 Hørsholm / DK
Former [2007/18]	Inspicos A/S Bøge Allé 5 P.O. Box 45 2970 Hørsholm / DK
Former [2005/48]	Nilausen, Kim, et al Zacco Denmark A/S, Hans Bekkevolds Allé 7 2900 Hellerup / DK
Application number, filing date	04714520.6	25.02.2004
	[2005/48]
	WO2004NO00051
Priority number, date	US20030450134P	25.02.2003 Original published format: US 450134 P
	US20040786907	25.02.2004 Original published format: US 786907
	[2005/48]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2004076489
	Date:	10.09.2004
	Language:	EN
	[2004/37]
	Type:	A1 Application with search report
	No.:	EP1599504
	Date:	30.11.2005
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 10.09.2004 takes the place of the publication of the European patent application.
	[2005/48]
	Type:	B1 Patent specification
	No.:	EP1599504
	Date:	03.12.2014
	Language:	EN
	[2014/49]
Search report(s)	International search report - published on:	SE	10.09.2004
Classification	IPC:	C07K16/46, C07K19/00	[2014/28]
	CPC:	C07K16/44 (EP,US); A61P31/00 (EP); A61P31/04 (EP); A61P31/06 (EP); A61P31/12 (EP); A61P31/18 (EP); (+) A61P35/00 (EP); A61P37/04 (EP); C07K14/005 (US); C07K14/34 (US); C07K14/70578 (US); C07K14/7158 (US); C07K16/28 (US); C07K16/2833 (EP,US); C12N9/1276 (EP,US); A61K2039/505 (EP,US); A61K2039/54 (EP,US); C07K2317/31 (EP,US); C07K2317/622 (EP,US); C07K2317/64 (EP,US); C07K2319/40 (US); C12N2740/16022 (US); C12N2740/16034 (US); C12Y207/07049 (EP,US) (-)
	Former IPC [2005/48]	C07K16/46, C07K19/00, // C07K16/42
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR [2005/48]
Title	German:	MODIFIZIERTER ANTIKÖRPER	[2005/48]
	English:	MODIFIED ANTIBODY	[2005/48]
	French:	ANTICORPS MODIFIE	[2005/48]
Entry into regional phase	21.09.2005	National basic fee paid
	21.09.2005	Designation fee(s) paid
	21.09.2005	Examination fee paid
Examination procedure	30.08.2004	Request for preliminary examination filed International Preliminary Examining Authority: SE
	21.09.2005	Examination requested [2005/48]
	23.01.2007	Despatch of a communication from the examining division (Time limit: M06)
	27.07.2007	Reply to a communication from the examining division
	12.03.2009	Despatch of a communication from the examining division (Time limit: M06)
	31.08.2009	Reply to a communication from the examining division
	14.02.2012	Despatch of a communication from the examining division (Time limit: M04)
	14.06.2012	Reply to a communication from the examining division
	05.05.2014	Cancellation of oral proceeding that was planned for 11.06.2014
	11.06.2014	Date of oral proceedings (cancelled)
	13.06.2014	Communication of intention to grant the patent
	23.10.2014	Fee for grant paid
	23.10.2014	Fee for publishing/printing paid
	23.10.2014	Receipt of the translation of the claim(s)
Divisional application(s)	EP14195614.4 / EP2862878
	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 23.01.2007
Opposition(s)	04.09.2015	No opposition filed within time limit [2015/46]
Fees paid	Renewal fee
	14.02.2006	Renewal fee patent year 03
	14.02.2007	Renewal fee patent year 04
	13.02.2008	Renewal fee patent year 05
	13.02.2009	Renewal fee patent year 06
	26.02.2010	Renewal fee patent year 07
	23.02.2011	Renewal fee patent year 08
	29.02.2012	Renewal fee patent year 09
	28.02.2013	Renewal fee patent year 10
	28.02.2014	Renewal fee patent year 11
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	BG	03.12.2014
	CY	03.12.2014
	EE	03.12.2014
	MC	03.12.2014
	RO	03.12.2014
	SI	03.12.2014
	SK	03.12.2014
	LU	25.02.2015
	[2017/39]
Former [2016/12]	CY	03.12.2014
	EE	03.12.2014
	MC	03.12.2014
	RO	03.12.2014
	SI	03.12.2014
	SK	03.12.2014
	LU	25.02.2015
Former [2015/46]	CY	03.12.2014
	EE	03.12.2014
	MC	03.12.2014
	RO	03.12.2014
	SK	03.12.2014
	LU	25.02.2015
Former [2015/44]	CY	03.12.2014
	EE	03.12.2014
	RO	03.12.2014
	SK	03.12.2014
	LU	25.02.2015
Former [2015/37]	CY	03.12.2014
	EE	03.12.2014
	RO	03.12.2014
	SK	03.12.2014
Former [2015/36]	CY	03.12.2014
	EE	03.12.2014
	RO	03.12.2014
Former [2015/35]	CY	03.12.2014
	EE	03.12.2014
Former [2015/26]	CY	03.12.2014
Cited in	International search	[A]US6099846 (LEVY RONALD [US], et al);
		[Y] - BIRAGYN A., ET AL., "Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity", NATURE BIOTECHNOLOGY, (199903), vol. 17, pages 253 - 258, XP002108131 DOI: http://dx.doi.org/10.1038/6995
		[X] - PLUCKTHUN A., ET AL., "New protein engineering approaches to multivalent and bispecific antibody fragments", IMMUNOTECHNOLOGY, (1997), vol. 3, pages 83 - 105, XP004126672 DOI: http://dx.doi.org/10.1016/S1380-2933(97)00067-5
		[X] - CHEN H.-W., "Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment", CANCER IMMUNOL IMMUNOTHER, (2002), vol. 51, pages 341 - 348, XP002979403 DOI: http://dx.doi.org/10.1007/s00262-002-0283-5
		[XP] - HUANG H.-I., "Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand", INT. J. CANCER, (2004), vol. 108, pages 696 - 703, XP002979404 DOI: http://dx.doi.org/10.1002/ijc.11612
		[X] - HUANG T.-H., ET AL., "Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen", BLOOD, (20001201), vol. 96, no. 12, pages 3663 - 3670, XP002955727
		[X] - KRIANGKUM J., ET AL., "Bispecific and bifunctional single chain recombinant antibodies", BIOMOLECULAR ENGINEERING, (2001), vol. 18, pages 31 - 40, XP004304464 DOI: http://dx.doi.org/10.1016/S1389-0344(01)00083-1
		[X] - VAN SPRIEL A. B., ET AL., "Immunotherapeutic perspective for bispecific antibodies", IMMUNOLOGY TODAY, (200008), vol. 21, no. 8, pages 391 - 397, XP004215167 DOI: http://dx.doi.org/10.1016/S0167-5699(00)01659-5
		[X] - HOOGENBOOM H. R., "Mix and match: Building manifold binding sites", NATURE BIOTECHNOLOGY, (199702), vol. 15, pages 125 - 126, XP002110046 DOI: http://dx.doi.org/10.1038/nbt0297-125
		[A] - HU S.-Z., ET AL., "Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-Chain Fv-Ch3) Which Exhibits Rapid, High-level Targeting of Xenografts", CANCER RESEARCH, (19960701), vol. 56, pages 3055 - 3061, XP002026337
		[A] - BIRAGYN A., ET AL., "Toll-Like Receptor 4-Dependent Activation of Dentritic Cells by beta-Defensin 2", SCIENCE, (20021101), vol. 298, pages 1025 - 1029, XP002979405 DOI: http://dx.doi.org/10.1126/science.1075565
		[A] - LUNDE E., ET AL., "Troybodies and Pepbodies", BIOCHEMICAL SOCIETY, (2002), vol. 30, pages 500 - 506, XP002227237 DOI: http://dx.doi.org/10.1042/BST0300500
		[A] - LUNDE E., ET AL., ""Troy-bodies": Recombinant Antibodies that Target T Cell Epitopes to Antigen Presenting Cells", INTERN. REV. IMMUNOL., (2001), vol. 20, pages 647 - 673, XP002979406
		[A] - RUFFINI P. A., ET AL., "Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines", HAEMATOLOGICA, (2002), vol. 87, pages 989 - 1001, XP002979407
		[X] - BRUNSVIK ET AL., "Construction of tetrabodies for cancer vaccines", BANFF 2003, XP003005727
		[X] - BRUNSVIK ET AL., "Construction of tetrabodies for cancer vaccines", BANFF 2003, XP003005728
		[X] - BRUNSVIK ET AL., "Vaccibodies: future vaccines for 8 celllymphoma and myeloma?", BANFF 2003, XP003005729
	Examination	- AGNETE BRUNSVIK FREDRIKSEN ET AL, "Chemokine-idiotype fusion DNAvaccines are potentiated by bivalency and xenogeneic sequences", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 110, doi:10.1182/BLOOD-2006-06-032938, ISSN 0006-4971, (20070101), pages 1797 - 1805, (20070531), XP007915509 DOI: http://dx.doi.org/10.1182/blood-2006-06-032938
		- DANIÈLE NOËL ET AL, "High In Vivo Production of a Model Monoclonal Antibody on Adenovital Gene Transfer", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 13, no. 12, doi:10.1089/10430340260185111, ISSN 1043-0342, (20020801), pages 1483 - 1493, (20020706), XP008112130 DOI: http://dx.doi.org/10.1089/10430340260185111
		- LEWIS A D ET AL, "Generation of Neutralizing Activity Against Human Immunodeficiency Virus Type 1 in Serum by Antibody Gene Transfer", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, (20020901), vol. 76, no. 17, doi:10.1128/JVI.76.17.8769-8775.2002, ISSN 0022-538X, pages 8769 - 8775, XP002992256 DOI: http://dx.doi.org/10.1128/JVI.76.17.8769-8775.2002
		- FREDRIKSEN ET AL, "DNA Vaccines Increase Immunogenicity of Idiotypic Tumor Antigen by Targeting Novel Fusion Proteins to Antigen-Presenting Cells", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, (20060401), vol. 13, no. 4, doi:10.1016/J.YMTHE.2005.10.019, ISSN 1525-0016, pages 776 - 785, XP005358612 DOI: http://dx.doi.org/10.1016/j.ymthe.2005.10.019
		- Karoline Schjetne ET AL, "Delivery of antigen to CD40 induces protective immune responses against tumors.", The Journal of Immunology, (20070401), vol. 178, no. 7, ISSN 0022-1767, pages 4169 - 4176, XP055058661 DOI: http://dx.doi.org/10.4049/jimmunol.178.7.4169
	by applicant	- BENDANDI, M.; C. D. GOCKE ET AL., "Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.", NAT MED, (1999), vol. 5, no. 10, doi:doi:10.1038/13928, pages 1171 - 7, XP003007895 DOI: http://dx.doi.org/10.1038/13928
		- BIRAGYN, A.; P. A. RUFFINI ET AL., "Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2.", SCIENCE, (2002), vol. 298, no. 5595, doi:doi:10.1126/science.1075565, pages 1025 - 9, XP002979405 DOI: http://dx.doi.org/10.1126/science.1075565
		- BIRAGYN, A.; K. TANI ET AL., "Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity.", NAT BIOTECHNOL, (1999), vol. 17, no. 3, doi:doi:10.1038/6995, pages 253 - 8, XP002108131 DOI: http://dx.doi.org/10.1038/6995
		- BOGEN, B., "Monoclonal antibodies specific for variable and constant domains of murine lambda chains.", SCAND J IMMUNOL, (1989), vol. 29, no. 3, pages 273 - 9
		- BOGEN, B.; PERIPHERAL T, "cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma", EUR J IMMUNOL., (199611), vol. 26, no. 11, pages 2671 - 9
		- BOGEN, B.; L. GLEDITSCH ET AL., "Weak positive selection of transgenic T cell receptor-bearing thymocytes: importance of major histocompatibility complex class II, T cell receptor and CD4 surface molecule densities.", EUR J IMMUNOL, (1992), vol. 22, no. 3, pages 703 - 9
		- BOGEN, B.; J. D. LAMBRIS, "Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule.", EMBO J, (1989), vol. 8, no. 7, pages 1947 - 52
		- BOGEN, B.; B. MALISSEN ET AL., "Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules.", EUR J IMMUNOL, (1986), vol. 16, no. 11, pages 1373 - 8
		- CASTEN, L. A.; S. K. PIERCE, "Receptor-mediated B cell antigen processing. Increased antigenicity of a globular protein covalently coupled to antibodies specific for B cell surface structures.", J IMMUNOL, (1988), vol. 140, no. 2, pages 404 - 10
		- EISEN, H. N.; E. S. SIMMS ET AL., "Mouse myeloma proteins with antihapten antibody acitivity. The protein produced by plasma cell tumor MOPC-315.", BIOCHEMISTRY, (1968), vol. 7, no. 11, pages 4126 - 34
		- HAKIM, I.; S. LEVY ET AL., "A nine-amino acid peptide from IL-lbeta augments antitumor immune responses induced by protein and DNA vaccines.", J IMMUNOL, (1996), vol. 157, no. 12, pages 5503 - 11, XP002167434
		- HOUGH, D. W.; R. P. EADY ET AL., "Anti-idiotype sera raised against surface immunoglobulin of human neoplastic lymphocytes.", J EXP MED, (1976), vol. 144, no. 4, doi:doi:10.1084/jem.144.4.960, pages 960 - 9, XP000992837 DOI: http://dx.doi.org/10.1084/jem.144.4.960
		- HUANG, H. I.; P. Y. WU ET AL., "Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand.", INT J CANCER, (2004), vol. 108, no. 5, doi:doi:10.1002/ijc.11612, pages 696 - 703, XP002979404 DOI: http://dx.doi.org/10.1002/ijc.11612
		- KING, C. A.; M. B. SPELLERBERG ET AL., "DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma.", NAT MED, (1998), vol. 4, no. 11, doi:doi:10.1038/3266, pages 1281 - 6, XP002339736 DOI: http://dx.doi.org/10.1038/3266
		- KRISTOFFERSEN, G.; K. HANNESTAD ET AL., "Two M315 idiotopes defined by isologous monoclonal antibodies: one depends on germline and the other on mutated murine lambda 2 light chain sequences.", SCAND J IMMUNOL, (1987), vol. 26, no. 5, pages 535 - 46
		- LAURITZSEN, G. F.; S. WEISS ET AL., "Anti-tumour activity of idiotype-specific, MHC-restricted Thl and Th2 clones in vitro and in vivo.", SCAND J IMMUNOL, (1993), vol. 37, no. 1, pages 77 - 85
		- LAURITZSEN, G. F.; S. WEISS ET AL., "Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors.", PROC NATL ACAD SCI U S A, (1994), vol. 91, no. 12, pages 5700 - 4
		- LUNDE, E.; L. A. MUNTHE ET AL., "Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells.", NAT BIOTECHNOL, (1999), vol. 17, no. 7, doi:doi:10.1038/10883, pages 670 - 5, XP002241695 DOI: http://dx.doi.org/10.1038/10883
		- LUNDE, E.; I. B. RASMUSSEN ET AL., "Troy-bodies': antibodies as vector proteins for T cell epitopes.", BIOMOL EN, (2001), vol. 18, no. 3, doi:doi:10.1016/S1389-0344(01)00091-0, pages 109 - 16, XP004305908 DOI: http://dx.doi.org/10.1016/S1389-0344(01)00091-0
		- LUNDE, E.; K. H. WESTERN ET AL., "Efficient delivery of T cell epitopes to APC by use of MHC class 11-specific Troybodies.", J IMMUNOL, (2002), vol. 168, no. 5, pages 2154 - 62
		- NEUBERGER, M. S., "Expression and regulation of immunoglobulin heavy chain gene transfected into lymphoid cells.", EMBO J, (1983), vol. 2, no. 8, pages 1373 - 8, XP002713612
		- NORDERHAUG, L.; T. OLAFSEN ET AL., "Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells.", J IMMUNOL METHODS, (1997), vol. 204, no. 1, doi:doi:10.1016/S0022-1759(97)00034-3, pages 77 - 87, XP004107719 DOI: http://dx.doi.org/10.1016/S0022-1759(97)00034-3
		- OLAFSEN, T.; 1. B. RASMUSSEN ET AL., "IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells.", IMMUNOTECHNOLOGY, (1998), vol. 4, no. 2, doi:doi:10.1016/S1380-2933(98)00014-1, pages 141 - 53, XP004153638 DOI: http://dx.doi.org/10.1016/S1380-2933(98)00014-1
		- OZATO, K.; N. MAYER ET AL., "Hybridoma cell lines secreting monoclonal antibodies to mouse H-2 and Ia antigens.", J IMMUNOL, (1980), vol. 124, no. 2, pages 533 - 40
		- RAVETCH, J. V.; S. BOLLAND, "IgG Fc receptors.", ANNU REV IMMUNOL, (2001), vol. 19, pages 275 - 90
		- SIRISINHA, S.; H. N. EISEN, "Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins.", PROC NATL ACAD SCI U S A, (1971), vol. 68, no. 12, pages 3130 - 5
		- SNIDER, D. P.; D. M. SEGAL, "Targeted antigen presentation using crosslinked antibody heteroaggregates.", J IMMUNOL, (1987), vol. 139, no. 5, pages 1609 - 16, XP002667340
		- TAO, M. H.; R. LEVY, "Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma.", NATURE, (1993), vol. 362, no. 6422, doi:doi:10.1038/362755a0, pages 755 - 8, XP002031411 DOI: http://dx.doi.org/10.1038/362755a0
		- TOLLEFSEN, S.; T. TJELLE ET AL., "Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation.", VACCINE, (2002), vol. 20, no. 27-28, doi:doi:10.1016/S0264-410X(02)00289-X, pages 3370 - 8, XP004378532 DOI: http://dx.doi.org/10.1016/S0264-410X(02)00289-X

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p